Scott Greisler Joins RealityRx

The healthcare tech agency focused on addressing the realities of the business world announces the hire of Scott Greisler to fill the role of Senior Vice President, Management Supervisor. Previously, Greisler held the role of Vice President, Group Account Director at Digitas Health for five years, where he managed multi-billion-dollar brands, including AbbVie’s Digital Humira (adalimumab) and Mylan team accounts.

At REALITYRx, Greisler will contribute to executive oversight of the Bracco Diagnostics account, including the solutions campaign aimed at unifying the company’s diverse portfolio, and the Amneal/Impax Laboratories account, particularly in regard to marketing and awareness campaigns for their generic for EpiPen. He brings more than 20 years of experience in the pharmaceutical and biotech industries to the agency, including expertise in business strategy, branding, product development, and launch preparation.

Prevail Promotes Emily Minkow

Prevail Therapeutics announces the promotion of Emily Minkow to Chief Business Officer. Minkow was previously the Executive VP of Business Development and Strategy for the biotechnology company that develops gene therapies for patients with Parkinson’s disease and other neurodegenerative and lysosomal disorders. “With our programs moving forward for patients with unmet needs in neurodegenerative and lysosomal disorders, our executive team brings the broad experience crucial to the future success of our mission,” said Asa Abeliovich, MD, PhD, Founder and Chief Executive Officer of Prevail. “We are very pleased to congratulate Emily on her well-deserved promotion to Chief Business Officer.”

Prior to Prevail, Minkow held positions of increasing responsibility at Celgene Corporation for seven years, most recently as the company’s Executive Director of Business Development.

Chameleon Communications

Former CEO Gary Hobbs steps down to a chairman position as Bill Mulligan steps in as the agency’s leader. Having previously served as President of U.S. Operations, Mulligan will now assume responsibility for the Chameleon Group worldwide. He spent 13 years with the company, from its time as a startup in New York.

eGenesis

The xenotransplantation firm brings on William “Wes” Westlin, PhD as Executive Vice President of Research & Development. He will help lead the Massachusetts-based company’s R&D of gene-editing CRISPR technology for making pig organs suitable for human transplantation to help with the persistently unmet demand for organs from human donors. Previously, Dr. Westlin has served as Senior VP of Preclinical Research and Early Development at both Nimbus Pharmaceuticals and Avila Therapeutics.

EUSA Pharmaceuticals

Jeffrey S. Hackman joins the specialty pharma firm as President of the company’s U.S. operations. He will be responsible for leading operations as the U.K.-based company establishes headquarters in Boston, Massachusetts. Hackman brings more than 30 years of experience to his new role, coming from his current position as interim CEO and Chief Operating Officer at Canadian firm, Novelion Therapeutics. He also served as Senior VP and Head of U.S. Internal Medicine/Oncology at Shire prior to that.

Gilead Sciences

Gilead names Gregg Alton as interim CEO until March when current Roche CEO Daniel O’Day will take on the role. Alton previously held a number of executive positions at Gilead during the past 20 years, with experience in legal, medical affairs, policy, and commercial. He previously served as general counsel, and in August of this year, he was appointed Chief Patient Officer.

IMV Inc.

Marc Jasmin joins the clinical stage immuno-oncology corporation in the newly created role of Senior Director, Investor Relations and Communications. Jasmin brings more than 15 years of experience to the company, having served in the Investor Relations department of Cascades and in a broad range of investor and communications-focused positions. Jasmin will help create and sustain long-term shareholder value and, ultimately, better options for patients and clinicians who remain underserved in today’s cancer treatment landscape.

Merck

The pharma giant announces two new executives: Frank Clyburn as Chief Commercial Officer and Michael Nally as Chief Marketing Officer. Clyburn leaves his role as President of the global oncology business since 2013 to take on global operations across Merck’s human health commercial portfolio. He worked throughout the market access, primary care, and women’s health divisions at Merck since 2009. Nally, who has been leading Merck’s vaccines unit, will now oversee global marketing and long-term franchise strategy across the portfolio. He will use the financial, investor relations, business development, strategic initiatives, and operations experience he has gained throughout his 15 years at Merck.

LNC Therapeutics

The French biotech made additions to its Board of Directors, including Catherine Combot-Plétan, PharmD, a strategy and project management expert for R&D and innovative biological drugs. Dr. Combot-Plétan is currently the President and Founder of ULTRace Development Partner, where she helps biotechnology companies and startups create value through R&D and acquisitions, providing strategic and operational support.

Relay Therapeutics

As the pharma leader continues to transition to a R&D stage biotech, it adds two new executives to its team. Mahesh Padval, PhD takes on the role of Senior VP of Pharmaceutical Drug Development, while Mary Mader, PhD, becomes VP of Chemistry. Previously VP of Pharmaceutical Sciences and Product Development at Verastem, Dr. Padval oversaw preclinical development, CMC, and clinical pharmacology activities. Dr. Mader previously served as a Senior Research Advisory and a Research Fellow at Eli Lilly, where she worked on the discovery and development of multiple clinical candidates. Prior to that, she was a Visiting Research Scientist at the Bayer Research Center and an Associate Professor at Grinnell College in Iowa.

Synergy Vision

As it gears up for global growth, the healthcare agency announces Vonnie Alexander as Non-executive Director. Along with the experience of growing an agency globally, Alexander also brings a commercially minded, yet empathetic and inspiring approach. Founder of ‘I am…’ executive and leadership coaching, she is a commercial business leader with more than 20 years of marketing services experience across small, large, independent, and networked agencies. In 2002, she co-founded Kitcatt Nohr, selling it to Publicis in 2011 and remaining as Managing Director until 2015.

Ads

You May Also Like

Orchestrating Your Brand

Picture this situation: Your company leader just held a town hall meeting and announced ...

Wanted: Specialty Pharma Marketer

Amidst the almost constant news about job cuts at pharma companies, there are certain ...

Mover and Shakers March 2020

Turning Point Therapeutics Names New EVP and Chief Scientific Officer Siegfried Reich, PhD, is ...